ARM Statement on the FDA Decision to Release a Clinical Hold on Geron's Embryonic Stem Cell Human Clinical Trial
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The Alliance for Regenerative Medicine (ARM), the advocacy voice for regenerative medicine, issued the following statement about the FDA's release of a clinical hold on Geron's human embryonic stem cell trial:
"FDA's release of the hold on Geron's Phase I embryonic stem cell trial in humans marks an important milestone for one of the regenerative medicine industry's leading companies, the resumption of the world's first human clinical study of an embryonic stem cell therapy. The regenerative medicine community is eager to see the progress of these potentially transformative therapies in patients so we can learn more about their clinical potential."
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations.
Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field.
"FDA's release of the hold on Geron's Phase I embryonic stem cell trial in humans marks an important milestone for one of the regenerative medicine industry's leading companies, the resumption of the world's first human clinical study of an embryonic stem cell therapy. The regenerative medicine community is eager to see the progress of these potentially transformative therapies in patients so we can learn more about their clinical potential."
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations.
Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field.
